Archives: IBN Spotlights

Beasley Broadcast Group Inc. (NASDAQ:BBGI) traded today at a new 52-week high of $17.70. This new high was reached on above average trading volume as 36.7 million shares traded hands, while the average 30-day volume is approximately 25,000 shares.

Beasley Broadcast Group Inc is a radio broadcasting company, engaged in operating radio stations throughout the United States. It operates radio stations including FM and AM radio stations located in large and mid-sized markets in the United States. The company owns and operates radio stations in the following radio markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, West Palm Beach-Boca Raton, FL, and Wilmington, DE. It is also a multi-platform, marketing solutions provider that offers on-air, online, and mobile and social media applications. The main source of revenue is the sale of advertising.

Potential upside of 1.7% exists for Beasley Broadcast Group Inc., based on a current level of $1.73 and analysts’ average consensus price target of $1.76.

In the past 52 weeks, Beasley Broadcast Group Inc. share prices are bracketed by a current low of $1.15 and a high of $3.39 and is now at $1.73.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Couchbase Inc. (NASDAQ:BASE) traded today at a new 52-week high of $52.51. This new high was reached on above average trading volume as 5.4 million shares traded hands, while the average 30-day volume is approximately 563,000 shares.

In the past 52 weeks, shares of Couchbase Inc. have traded between the current low of $14.68 and a high of $52.26 and is now at $17.11.

Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a highly scalable and available platform.

Based on a current price of $17.11, Couchbase Inc. is currently 0.2% above its average consensus analyst price target of $17.07.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Bandwidth Inc. (NASDAQ:BAND) traded today at $198.60, eclipsing its 52-week high. This new high was reached on above average trading volume as 15.2 million shares traded hands, while the average 30-day volume is approximately 866,000 shares.

There is potential upside of 1.8% for shares of Bandwidth Inc. based on a current price of $32.35 and an average consensus analyst price target of $32.92.

Bandwidth Inc engages in the business of providing a cloud-based communications platform for enterprises in the United States. The company’s solutions consist of software application programming interface for voice and text functionality and its owned and managed purpose-built internet protocol voice network. The segments of the company are Communications Platform-as-a-Service (CPaaS) and Other, of which a majority of the revenue is derived from the CPaaS segment. CPaaS revenue is derived from the provision of voice usage, phone number services, 911-enabled phone number services, messaging services and other services. It has the business presence in the United States and international countries, of which key revenue is derived from the United States.

Bandwidth Inc. share prices have moved between a 52-week high of $145.97 and the current low of $18.05 and are currently at $32.35 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

AutoZone Inc. (NYSE:AZO) traded at a new 52-week high today of $2221.57. So far today approximately 62,000 shares have been exchanged, as compared to an average 30-day volume of 204,000 shares.

AutoZone Inc. (NYSE:AZO) is currently priced 18.6% above its average consensus analyst price target of $1803.25.

Over the past year, AutoZone Inc. has traded in a range of $1367.96 to $2221.57 and is now at $2214.36, 62% above that low.

AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) traded at a new 52-week high today of $13.07. So far today approximately 383.9 million shares have been exchanged, as compared to an average 30-day volume of 175,000 shares.

Aytu BioPharma Inc. share prices have moved between a 52-week high of $7.47 and the current low of $0.25 and are currently at $1.00 per share.

Based on a current price of $1.00, Aytu BioPharma Inc. is currently 2.5% above its average consensus analyst price target of $0.97.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company’s primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of AXT Inc (NASDAQ:AXTI) traded today at $15.79, eclipsing its 52-week high. So far today approximately 43.7 million shares have been exchanged, as compared to an average 30-day volume of 138,000 shares.

In the past 52 weeks, shares of AXT Inc have traded between the current low of $1.86 and a high of $12.46 and is now at $6.44.

AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific of which China derives maximum revenue to the company.

AXT Inc has overhead space with shares priced $6.44, or 2.4% below the average consensus analyst price target of $6.60.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Axon Enterprise Inc. (NASDAQ:AXON) traded today at $212.25, eclipsing its 52-week high. Approximately 96.8 million shares have changed hands today, as compared to an average 30-day volume of 424,000 shares.

In the past 52 weeks, Axon Enterprise Inc. share prices are bracketed by a current low of $0.91 and a high of $209.00 and is now at $131.62.

Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software & sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and gets most of its revenue from the United States.

Axon Enterprise Inc. (NASDAQ:AXON) is currently priced 0.3% above its average consensus analyst price target of $131.20.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Axcella Health Inc. (NASDAQ:AXLA) traded at a new 52-week high today of $15.91. Approximately 8.1 million shares have changed hands today, as compared to an average 30-day volume of 88,000 shares.

Axcella Health Inc. (NASDAQ:AXLA) is currently priced 1.8% above its average consensus analyst price target of $2.72.

Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company’s pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.

In the past 52 weeks, shares of Axcella Health Inc. have traded between a low of $1.44 and a high of $15.91 and is now at $2.77, which is 92% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Aspira Women’s Health Inc. (NASDAQ:AWH) traded today at $54.46, eclipsing its 52-week high. This new high was reached on above average trading volume as 32 million shares traded hands, while the average 30-day volume is approximately 429,000 shares.

Aspira Womens Health Inc is transforming women’s health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.

In the past 52 weeks, Aspira Women’s Health Inc. share prices are bracketed by a low of $0.87 and a high of $54.46 and is now at $0.93, 7% above that low price.

Potential upside of 1.9% exists for Aspira Women’s Health Inc., based on a current level of $0.93 and analysts’ average consensus price target of $0.95.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

AVROBIO Inc. (NASDAQ:AVRO) traded today at a new 52-week high of $53.19. Approximately 18.2 million shares have changed hands today, as compared to an average 30-day volume of 355,000 shares.

In the past 52 weeks, AVROBIO Inc. share prices are bracketed by a current low of $1.17 and a high of $12.15 and is now at $1.22.

AVROBIO Inc. (NASDAQ:AVRO) has potential upside of 14.3% based on a current price of $1.22 and analysts’ consensus price target of $1.40.

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company’s pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Aviat Networks Inc. (NASDAQ:AVNW) traded today at a new 52-week high of $87.41. Approximately 9.5 million shares have changed hands today, as compared to an average 30-day volume of 75,000 shares.

There is potential upside of 1.8% for shares of Aviat Networks Inc. based on a current price of $29.00 and an average consensus analyst price target of $29.54.

Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies and broadcast network operators around the world. The company’s product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly-licensed and license-exempt (operating in license-exempt frequencies), and element and network management software. Primarily the firm’s concentrations for most of the Sales and Service resources are in the United States, Western and Southern Africa, the Philippines, and the European Union.

Aviat Networks Inc. share prices have moved between a 52-week high of $43.76 and the current low of $0.55 and are currently at $29.00 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Atea Pharmaceuticals Inc. (NASDAQ:AVIR) traded today at $93.80, eclipsing its 52-week high. This new high was reached on above average trading volume as 62.4 million shares traded hands, while the average 30-day volume is approximately 993,000 shares.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company’s medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

There is potential upside of 1.1% for shares of Atea Pharmaceuticals Inc. based on a current price of $6.63 and an average consensus analyst price target of $6.70.

In the past 52 weeks, Atea Pharmaceuticals Inc. share prices are bracketed by a current low of $0.44 and a high of $59.82 and is now at $6.63.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Avid Technology Inc. (NASDAQ:AVID) traded at a new 52-week high today of $44.42. Approximately 43 million shares have changed hands today, as compared to an average 30-day volume of 383,000 shares.

There is potential upside of 0.6% for shares of Avid Technology Inc. based on a current price of $34.18 and an average consensus analyst price target of $34.38.

Avid Technology Inc. share prices have moved between a 52-week high of $40.48 and the current low of $3.99 and are currently at $34.18 per share.

Avid Technology Inc develops and sells software and hardware for digital media production and management. Its products are used in production, film studios, cable television stations, recording studios, and other agencies. The company has operations in the U.S.; the Americas; Europe, Middle East, and Africa; and Asia-Pacific. Most of its revenue is split fairly evenly between the U.S. and EMEA. The company’s products are organized into suites, including Artist Suite, which includes video editing and digital audio workstations; Media Suite, which provides newsroom management solutions; Studio Suite, which provides tools for on-air programming; and Storage Suite, which provides products for digital storage. It derives most of the revenue from video and audio products and services.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) traded at a new 52-week high today of $23.40. This new high was reached on above average trading volume as 265.6 million shares traded hands, while the average 30-day volume is approximately 371,000 shares.

There is potential upside of 1.2% for shares of AVEO Pharmaceuticals Inc. based on a current price of $5.88 and an average consensus analyst price target of $5.95.

In the past 52 weeks, shares of AVEO Pharmaceuticals Inc. have traded between the current low of $0.47 and a high of $7.58 and is now at $5.88.

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Avadel Pharmaceuticals plc (NASDAQ:AVDL) traded at a new 52-week high today of $15.50. This new high was reached on above average trading volume as 38.6 million shares traded hands, while the average 30-day volume is approximately 378,000 shares.

Over the past year, Avadel Pharmaceuticals plc has traded in a range of $1.01 to $11.59 and is now at $6.76.

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is currently priced 0.4% above its average consensus analyst price target of $6.73.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of AutoWeb Inc. (NASDAQ:AUTO) traded today at $9.91, eclipsing its 52-week high. Approximately 18.9 million shares have changed hands today, as compared to an average 30-day volume of 29,000 shares.

AutoWeb Inc is a digital marketing company for the automotive industry. The company helps automotive retail dealers and automotive manufacturers to market and sell new and used vehicles to consumers through the company’s programs for online lead and traffic referrals, dealer marketing products and services, online advertising and mobile products.

In the past 52 weeks, shares of AutoWeb Inc. have traded between the current low of $0.52 and a high of $4.35 and is now at $2.53.

AutoWeb Inc. (NASDAQ:AUTO) is currently priced 1.4% above its average consensus analyst price target of $2.49.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Autolus Therapeutics plc (NASDAQ:AUTL) traded at a new 52-week high today of $53.24. This new high was reached on above average trading volume as 30.9 million shares traded hands, while the average 30-day volume is approximately 282,000 shares.

In the past 52 weeks, Autolus Therapeutics plc share prices are bracketed by a current low of $3.08 and a high of $8.23 and is now at $4.41.

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company’s clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Potential upside of 3.3% exists for Autolus Therapeutics plc, based on a current level of $4.41 and analysts’ average consensus price target of $4.55.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Antares Pharma Inc. (NASDAQ:ATRS) traded at a new 52-week high today of $5.15. This new high was reached on above average trading volume as 136.2 million shares traded hands, while the average 30-day volume is approximately 924,000 shares.

Based on a current price of $4.00, Antares Pharma Inc. is currently 1.2% above its average consensus analyst price target of $3.95.

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company’s products include OTREXUP, Elestrin, Gelnique, Makena, and others.

In the past 52 weeks, shares of Antares Pharma Inc. have traded between the current low of $0.70 and a high of $4.63 and is now at $4.00.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded today at $54.45, eclipsing its 52-week high. Approximately 42.6 million shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares.

In the past 52 weeks, Atara Biotherapeutics Inc. share prices are bracketed by a current low of $4.58 and a high of $20.04 and is now at $9.00.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company’s product candidates comprise Tab-cel, ATA188, and CAR T Programs.

Potential upside of 4.9% exists for Atara Biotherapeutics Inc., based on a current level of $9.00 and analysts’ average consensus price target of $9.44.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Athenex Inc. (NASDAQ:ATNX) traded at a new 52-week high today of $23.00. Approximately 91.4 million shares have changed hands today, as compared to an average 30-day volume of 900,000 shares.

In the past 52 weeks, Athenex Inc. share prices are bracketed by a low of $0.73 and a high of $23.00 and is now at $0.77, 6% above that low price.

Based on a current price of $0.77, Athenex Inc. is currently 0.3% above its average consensus analyst price target of $0.77.

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Athersys Inc. (NASDAQ:ATHX) traded at a new 52-week high today of $4.49. This new high was reached on above average trading volume as 148.6 million shares traded hands, while the average 30-day volume is approximately 1.8 million shares.

In the past 52 weeks, Athersys Inc. share prices are bracketed by a current low of $0.46 and a high of $1.93 and is now at $0.53.

Athersys Inc. (NASDAQ:ATHX) has potential upside of 3.8% based on a current price of $0.53 and analysts’ consensus price target of $0.55.

Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm’s main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Alterity Therapeutics Limited (NASDAQ:ATHE) traded today at a new 52-week high of $6.12. So far today approximately 132.7 million shares have been exchanged, as compared to an average 30-day volume of 106,000 shares.

In the past 52 weeks, shares of Alterity Therapeutics Limited have traded between the current low of $0.28 and a high of $2.75 and is now at $0.82.

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer’s disease, Huntington disease, and other neurodegenerative disorders. The company’s lead drug candidate-PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. It has also advanced a drug candidate for Parkinson’s disease and other movement disorders (ATH434).

Alterity Therapeutics Limited (NASDAQ:ATHE) has potential upside of 85.4% based on a current price of $0.82 and analysts’ consensus price target of $1.52.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Anterix Inc. (NASDAQ:ATEX) traded today at $66.71, eclipsing its 52-week high. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 75,000 shares.

There is potential upside of 56.0% for shares of Anterix Inc. based on a current price of $56.98 and an average consensus analyst price target of $88.89.

Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. It offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.

In the past 52 weeks, Anterix Inc. share prices are bracketed by a current low of $27.44 and a high of $66.55 and is now at $56.98.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Alphatec Holdings Inc. (NASDAQ:ATEC) traded today at $19.50, eclipsing its 52-week high. Approximately 40 million shares have changed hands today, as compared to an average 30-day volume of 679,000 shares.

Alphatec Holdings Inc. share prices have moved between a 52-week high of $18.00 and the current low of $0.18 and are currently at $12.54 per share.

Alphatec Holdings Inc. (NASDAQ:ATEC) has potential upside of 2.2% based on a current price of $12.54 and analysts’ consensus price target of $12.81.

Alphatec Holdings Inc is a medical technology company focused on the design, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The firm’s spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Amtech Systems Inc. (NASDAQ:ASYS) traded today at $16.44, eclipsing its 52-week high. This new high was reached on above average trading volume as 16.8 million shares traded hands, while the average 30-day volume is approximately 53,000 shares.

Based on a current price of $9.79, Amtech Systems Inc. is currently 14.2% above its average consensus analyst price target of $8.40.

Amtech Systems Inc is a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon carbide (SiC) and silicon power chips, electronic assemblies and light-emitting diodes (LEDs). Its segments comprise Semiconductor, SiC/LED, and others. The company generates maximum revenue from the Semiconductor segment. Its Semiconductor segment is engaged in design, manufacture, sell and service thermal processing equipment and related controls for use by leading semiconductor manufacturers, and in electronics, automotive, and other industries. Geographically, it derives a majority of revenue from the United States.

In the past 52 weeks, Amtech Systems Inc. share prices are bracketed by a current low of $3.63 and a high of $15.78 and is now at $9.79.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Aspen Group Inc. (NASDAQ:ASPU) traded at a new 52-week high today of $13.14. This new high was reached on above average trading volume as 11 million shares traded hands, while the average 30-day volume is approximately 157,000 shares.

Aspen Group Inc. (NASDAQ:ASPU) has potential upside of 19.4% based on a current price of $1.08 and analysts’ consensus price target of $1.29.

In the past 52 weeks, shares of Aspen Group Inc. have traded between the current low of $0.90 and a high of $7.49 and is now at $1.08.

Aspen Group Inc is an education technology holding company that leverages its infrastructure and expertise to allow its two universities, Aspen University and United States University, to deliver on the vision of making college affordable again. Its only segment being educational delivery operation using a core infrastructure that serves the curriculum and educational delivery needs of its online and campus students regardless of geography.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) traded today at a new 52-week high of $10.40. So far today approximately 54.1 million shares have been exchanged, as compared to an average 30-day volume of 186,000 shares.

ASLAN Pharmaceuticals Limited has overhead space with shares priced $0.82, or 4.0% below the average consensus analyst price target of $0.85.

In the past 52 weeks, ASLAN Pharmaceuticals Limited share prices are bracketed by a current low of $0.36 and a high of $3.87 and is now at $0.82.

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Ardmore Shipping Corporation (NYSE:ASC) traded at a new 52-week high today of $5.25. So far today approximately 283,000 shares have been exchanged, as compared to an average 30-day volume of 236,000 shares.

Ardmore Shipping Corporation share prices have moved between a 52-week high of $5.25 and a 52-week low of $3.07 and are now trading 66% above that low price at $5.11 per share.

Ardmore Shipping Corp owns and operates a fleet of mid-size product and chemical tankers, which provide seaborne transportation of petroleum products and chemicals across the globe. The company is focused on fuel efficiency and cost leadership, and it provides its shipping services to customers through voyage charters, commercial pools, and time charters. Its main customers are oil majors, national oil companies, oil and chemical traders, and chemical companies.

Ardmore Shipping Corporation (NYSE:ASC) defies analysts with a current price ($5.11) 4.4% above its average consensus price target of $4.88.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Alliance Resource Partners L.P. (NASDAQ:ARLP) traded at a new 52-week high today of $26.60. This new high was reached on above average trading volume as 69.4 million shares traded hands, while the average 30-day volume is approximately 753,000 shares.

Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments Illinois Basin, Appalachia, Oil & Gas Royalties and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland and West Virginia and it makes up for most of the company’s revenue-generating operations. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex and the MC Mining mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II and includes Alliance Minerals’ equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties has includes coal mineral reserves and resources owned or leased by Alliance Resource Properties.

Alliance Resource Partners L.P. (NASDAQ:ARLP) is currently priced 1.0% above its average consensus analyst price target of $15.23.

In the past 52 weeks, Alliance Resource Partners L.P. share prices are bracketed by a current low of $2.63 and a high of $16.35 and is now at $15.38.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded today at $129.60, eclipsing its 52-week high. So far today approximately 33.7 million shares have been exchanged, as compared to an average 30-day volume of 547,000 shares.

Arcturus Therapeutics Holdings Inc. has overhead space with shares priced $27.58, or 8.6% below the average consensus analyst price target of $30.19.

Arcturus Therapeutics Holdings Inc. share prices have moved between a 52-week high of $65.00 and the current low of $4.19 and are currently at $27.58 per share.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Accuray Incorporated (NASDAQ:ARAY) traded today at a new 52-week high of $6.39. So far today approximately 56.2 million shares have been exchanged, as compared to an average 30-day volume of 590,000 shares.

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company’s technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis.

Accuray Incorporated (NASDAQ:ARAY) is currently priced 46.5% above its average consensus analyst price target of $1.69.

Accuray Incorporated share prices have moved between a 52-week high of $5.93 and the current low of $1.33 and are currently at $3.17 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Aravive Inc. (NASDAQ:ARAV) traded at a new 52-week high today of $29.60. Approximately 17.2 million shares have changed hands today, as compared to an average 30-day volume of 55,000 shares.

In the past 52 weeks, shares of Aravive Inc. have traded between the current low of $1.28 and a high of $6.94 and is now at $1.80.

Potential upside of 7.8% exists for Aravive Inc., based on a current level of $1.80 and analysts’ average consensus price target of $1.94.

Aravive Inc is a clinical-stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. The company’s lead candidate AVB-500 is developed as a targeted therapy against ovarian cancer.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Antero Resources Corporation (NYSE:AR) traded today at $33.35, eclipsing its 52-week high. This new high was reached on below average trading volume as 2.7 million shares traded hands, while the average 30-day volume is approximately 8.3 million shares.

Antero Resources Corporation (NYSE:AR) is currently priced 3.2% above its average consensus analyst price target of $31.64.

Antero Resources, based in Denver, engages in the exploration for and production of natural gas and natural gas liquids in the United States and Canada. At the end of 2021, the company reported proven reserves of 17.7 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,268 million cubic feet of equivalent a day in 2021 at a ratio of 31% liquids and 69% natural gas.

Over the past year, Antero Resources Corporation has traded in a range of $8.81 to $33.35 and is now at $32.69, 271% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Apyx Medical Corporation (NASDAQ:APYX) traded at a new 52-week high today of $19.60. So far today approximately 6.8 million shares have been exchanged, as compared to an average 30-day volume of 147,000 shares.

There is potential upside of 5.4% for shares of Apyx Medical Corporation based on a current price of $5.93 and an average consensus analyst price target of $6.25.

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor’s offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of revenue.

In the past 52 weeks, shares of Apyx Medical Corporation have traded between the current low of $2.81 and a high of $17.50 and is now at $5.93.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) traded today at $9.45, eclipsing its 52-week high. This new high was reached on above average trading volume as 101.8 million shares traded hands, while the average 30-day volume is approximately 429,000 shares.

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton’s tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.

Aptose Biosciences Inc. (NASDAQ:APTO) is currently priced 0.2% above its average consensus analyst price target of $1.39.

In the past 52 weeks, Aptose Biosciences Inc. share prices are bracketed by a current low of $0.65 and a high of $5.86 and is now at $1.39.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Applied Therapeutics Inc. (NASDAQ:APLT) traded at a new 52-week high today of $57.37. This new high was reached on above average trading volume as 6.2 million shares traded hands, while the average 30-day volume is approximately 295,000 shares.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

Applied Therapeutics Inc. (NASDAQ:APLT) is currently priced 5.6% above its average consensus analyst price target of $2.47.

In the past 52 weeks, Applied Therapeutics Inc. share prices are bracketed by a current low of $1.45 and a high of $25.59 and is now at $2.62.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Apollo Endosurgery Inc. (NASDAQ:APEN) traded today at $21.86, eclipsing its 52-week high. This new high was reached on above average trading volume as 14.6 million shares traded hands, while the average 30-day volume is approximately 138,000 shares.

In the past 52 weeks, shares of Apollo Endosurgery Inc. have traded between the current low of $1.25 and a high of $10.39 and is now at $6.02.

Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focusses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company’s products include ORBERA, LAP-BAND and OverStitch.

Apollo Endosurgery Inc. (NASDAQ:APEN) is currently priced 3.1% above its average consensus analyst price target of $5.83.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Applied DNA Sciences Inc. (NASDAQ:APDN) traded at a new 52-week high today of $20.00. Approximately 76.6 million shares have changed hands today, as compared to an average 30-day volume of 93,000 shares.

There is potential upside of 8.5% for shares of Applied DNA Sciences Inc. based on a current price of $2.00 and an average consensus analyst price target of $2.17.

In the past 52 weeks, shares of Applied DNA Sciences Inc. have traded between the current low of $0.17 and a high of $9.96 and is now at $2.00.

Applied DNA Sciences Inc is a provider of DNA-based supply chain, anti-counterfeiting, and anti-theft technology. The company provides its products and services under the brand of SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon. It serves clients in various industries including government/military, security and asset marking, industrial parts, pharmaceuticals, textiles and apparel, and printing and packaging. The company has operational footprints across the United States, Europe, Asia, and others. Key revenue is derived from Americas.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Aon plc Class A (Ireland) (NYSE:AON) traded at a new 52-week high today of $336.12. This new high was reached on below average trading volume as 139,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares.

Aon plc Class A (Ireland) (NYSE:AON) is currently priced 1.5% above its average consensus analyst price target of $330.55.

Aon plc Class A (Ireland) share prices have moved between a 52-week high of $336.12 and a 52-week low of $223.19 and are now trading 50% above that low price at $335.46 per share.

Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Anthem Inc. (NYSE:ANTM) traded today at $526.62, eclipsing its 52-week high. Approximately 468,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares.

Anthem Inc. (NYSE:ANTM) defies analysts with a current price ($522.99) 3.1% above its average consensus price target of $506.97.

Anthem remains one of leading health insurers in the U.S., providing medical benefits to roughly 45 million medical members. The company offers employer, individual, and government-sponsored coverage plans. Anthem differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Anthem’s reach expands beyond those states through government-sponsored programs such as Medicaid, too.

Over the past year, Anthem Inc. has traded in a range of $350.46 to $526.62 and is now at $522.99, 49% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Anixa Biosciences Inc. (NASDAQ:ANIX) traded today at a new 52-week high of $8.10. Approximately 22.9 million shares have changed hands today, as compared to an average 30-day volume of 54,000 shares.

Anixa Biosciences Inc. share prices have moved between a 52-week high of $5.87 and the current low of $1.34 and are currently at $2.68 per share.

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body’s immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body’s immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient’s own immune cells to fight cancer.

Anixa Biosciences Inc. (NASDAQ:ANIX) is currently priced 9.7% above its average consensus analyst price target of $2.42.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) traded today at $86.44, eclipsing its 52-week high. Approximately 12.2 million shares have changed hands today, as compared to an average 30-day volume of 187,000 shares.

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) is currently priced 2.0% above its average consensus analyst price target of $29.58.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Over the past year, ANI Pharmaceuticals Inc. has traded in a range of $23.60 to $60.23 and is now at $30.17.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Angi Inc. (NASDAQ:ANGI) traded today at $23.95, eclipsing its 52-week high. So far today approximately 97.2 million shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares.

Over the past year, Angi Inc. has traded in a range of $4.13 to $17.54 and is now at $5.41.

Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie’s List, Handy, mHelpDesk, HomeStars, and Fixd Repair; and Europe, which includes the operations of Travaux, MyHammer, MyBuilder, Werkspot, and Instapro. The company generates maximum revenue from the North American segment.

Angi Inc. (NASDAQ:ANGI) has potential upside of 6.1% based on a current price of $5.41 and analysts’ consensus price target of $5.74.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

American Superconductor Corporation (NASDAQ:AMSC) traded today at a new 52-week high of $31.75. So far today approximately 29 million shares have been exchanged, as compared to an average 30-day volume of 319,000 shares.

American Superconductor Corp generates the ideas, technologies, and solutions that meet world’s demand for smarter, cleaner and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency and performance. The company’s solutions are powering gigawatts of renewable energy and enhancing the performance and reliability of power networks.

Over the past year, American Superconductor Corporation has traded in a range of $2.90 to $19.63 and is now at $7.07.

Potential upside of 22.3% exists for American Superconductor Corporation, based on a current level of $7.07 and analysts’ average consensus price target of $8.65.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Amyris Inc. (NASDAQ:AMRS) traded today at $23.33, eclipsing its 52-week high. So far today approximately 298.6 million shares have been exchanged, as compared to an average 30-day volume of 4.5 million shares.

Amyris Inc. share prices have moved between a 52-week high of $18.75 and the current low of $0.22 and are currently at $4.55 per share.

Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services.

Amyris Inc. (NASDAQ:AMRS) is currently priced 2.4% above its average consensus analyst price target of $4.44.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of AMC Networks Inc. (NASDAQ:AMCX) traded today at $83.78, eclipsing its 52-week high. Approximately 46.5 million shares have changed hands today, as compared to an average 30-day volume of 521,000 shares.

In the past 52 weeks, AMC Networks Inc. share prices are bracketed by a current low of $19.68 and a high of $72.80 and is now at $38.27.

AMC Networks Inc. (NASDAQ:AMCX) has potential upside of 1.2% based on a current price of $38.27 and analysts’ consensus price target of $38.73.

AMC Networks owns several cable networks, including flagship AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, the most widely distributed channel, reaches more than 78 million pay-TV households in the U.S. Over the last decade, AMC shifted its focus to original scripted programming from classic movies. WE tv targets a female audience and reaches roughly 76 million households. IFC mainly shows independent films and alternative comedy series. AMC also operates a number of niche streaming platforms including Acorn (focused on British shows) and Shudder (focused on horror programming). The firm launched AMC+, a streaming platform for its own content in 2020.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

ALX Oncology Holdings Inc. (NASDAQ:ALXO) traded today at a new 52-week high of $117.45. Approximately 4.1 million shares have changed hands today, as compared to an average 30-day volume of 362,000 shares.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Potential upside of 12.9% exists for ALX Oncology Holdings Inc., based on a current level of $16.97 and analysts’ average consensus price target of $19.16.

In the past 52 weeks, ALX Oncology Holdings Inc. share prices are bracketed by a low of $13.22 and a high of $117.45 and is now at $16.97, 28% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Altimmune Inc. (NASDAQ:ALT) traded at a new 52-week high today of $36.25. Approximately 131.8 million shares have changed hands today, as compared to an average 30-day volume of 1 million shares.

Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm’s product candidates include NasoVAX, HepTcell, ALT-801, T-COVID, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

There is potential upside of 0.9% for shares of Altimmune Inc. based on a current price of $5.82 and an average consensus analyst price target of $5.88.

In the past 52 weeks, Altimmune Inc. share prices are bracketed by a current low of $0.23 and a high of $19.46 and is now at $5.82.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Aileron Therapeutics Inc. (NASDAQ:ALRN) traded at a new 52-week high today of $15.33. Approximately 65.9 million shares have changed hands today, as compared to an average 30-day volume of 488,000 shares.

Aileron Therapeutics Inc. has overhead space with shares priced $0.65, or 7.1% below the average consensus analyst price target of $0.70.

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company’s lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.

Aileron Therapeutics Inc. share prices have moved between a 52-week high of $1.42 and the current low of $0.25 and are currently at $0.65 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at a new 52-week high of $54.80. So far today approximately 38.5 million shares have been exchanged, as compared to an average 30-day volume of 1.7 million shares.

In the past 52 weeks, Allogene Therapeutics Inc. share prices are bracketed by a current low of $7.14 and a high of $35.88 and is now at $9.08.

Potential upside of 4.1% exists for Allogene Therapeutics Inc., based on a current level of $9.08 and analysts’ average consensus price target of $9.45.

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Allstate Corporation (The) (NYSE:ALL) traded at a new 52-week high today of $142.40. This new high was reached on below average trading volume as 454,000 shares traded hands, while the average 30-day volume is approximately 2.1 million shares.

In the past 52 weeks, Allstate Corporation (The) share prices are bracketed by a low of $106.11 and a high of $142.40 and is now at $141.38, 33% above that low price.

On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.

Allstate Corporation (The) (NYSE:ALL) is currently priced 1.7% above its average consensus analyst price target of $138.94.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Alkermes plc (NASDAQ:ALKS) traded at a new 52-week high today of $71.07. This new high was reached on above average trading volume as 68.9 million shares traded hands, while the average 30-day volume is approximately 1.3 million shares.

Over the past year, Alkermes plc has traded in a range of $12.03 to $33.00 and is now at $29.75.

Based on a current price of $29.75, Alkermes plc is currently 0.8% above its average consensus analyst price target of $29.52.

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Alimera Sciences Inc. (NASDAQ:ALIM) traded at a new 52-week high today of $13.50. Approximately 28.5 million shares have changed hands today, as compared to an average 30-day volume of 33,000 shares.

Alimera Sciences Inc. (NASDAQ:ALIM) defies analysts with a current price ($6.00) 7.1% above its average consensus price target of $5.58.

In the past 52 weeks, Alimera Sciences Inc. share prices are bracketed by a current low of $0.00 and a high of $11.85 and is now at $6.00.

Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera’s a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product’s novel drug delivery technology.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) traded today at a new 52-week high of $16.65. This new high was reached on above average trading volume as 66.3 million shares traded hands, while the average 30-day volume is approximately 919,000 shares.

In the past 52 weeks, shares of Aldeyra Therapeutics Inc. have traded between the current low of $1.50 and a high of $15.95 and is now at $4.59.

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) has potential upside of 4.9% based on a current price of $4.59 and analysts’ consensus price target of $4.82.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company’s product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Akoustis Technologies Inc. (NASDAQ:AKTS) traded at a new 52-week high today of $19.18. So far today approximately 43.9 million shares have been exchanged, as compared to an average 30-day volume of 454,000 shares.

There is potential upside of 10.3% for shares of Akoustis Technologies Inc. based on a current price of $6.01 and an average consensus analyst price target of $6.63.

Akoustis Technologies Inc. share prices have moved between a 52-week high of $13.70 and the current low of $3.42 and are currently at $6.01 per share.

Akoustis Technologies Inc is an emerging commercial product company focused on developing, designing, and manufacturing innovative RF filter solutions for the wireless industry, including for products such as smartphones and tablets, network infrastructure equipment, WiFi Customer Premise Equipment and defense applications. The company has developed a proprietary microelectromechanical system based bulk acoustic wave technology and a unique manufacturing process flow, called XBAW, for filters produced for use in RFFE modules. The company derives revenue from the sale of filter products under individual customer purchase orders, some of which have underlying master sales agreements that specify terms governing the product sales.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Arthur J. Gallagher & Co. (NYSE:AJG) traded at a new 52-week high today of $182.98. Approximately 167,000 shares have changed hands today, as compared to an average 30-day volume of 956,000 shares.

Arthur J. Gallagher & Co. (NYSE:AJG) is currently priced 2.0% above its average consensus analyst price target of $179.11.

Over the past year, Arthur J. Gallagher & Co. has traded in a range of $128.69 to $182.98 and is now at $182.77, 42% above that low.

Arthur J. Gallagher & Co provides insurance brokerage and consulting services to middle-market entities around the world. The majority of the company’s revenue comes from its brokerage segment, where it negotiates and places its customers with insurance companies that provide, among other types, property/casualty and health insurance. The company’s primary source of revenue in the brokerage segment is commissioning from the insurance companies. The company also generates significant revenue in its corporate segment, which includes clean energy investment and other investment income. The company generates most of its revenue in the United States, with the remaining revenue coming primarily from Australia, Bermuda, Canada, the Caribbean, New Zealand, and the United Kingdom.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Assurant Inc. (NYSE:AIZ) traded at a new 52-week high today of $187.70. Approximately 61,000 shares have changed hands today, as compared to an average 30-day volume of 405,000 shares.

Assurant Inc offers a range of property-casualty, health, employee benefit, and warranty insurance to a client base made up of individuals and institutions. Its segments are Global Housing, Global Lifestyle, Corporate and Other. Global Housing segment, the key revenue-generating segment, provides lender-placed homeowners insurance, lender-placed manufactured housing insurance and lender-placed flood insurance; renters insurance and related products; and voluntary manufactured housing insurance, voluntary homeowners insurance and other specialty products. Global Lifestyle provides mobile device solutions and extended service products and related services for mobile devices, consumer electronics and appliances; vehicle protection; and credit protection and other insurance products.

Assurant Inc. (NYSE:AIZ) is currently priced 1.5% above its average consensus analyst price target of $184.80.

In the past 52 weeks, Assurant Inc. share prices are bracketed by a low of $142.99 and a high of $187.70 and is now at $187.60, 31% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Apollo Investment Corporation (NASDAQ:AINV) traded today at $18.32, eclipsing its 52-week high. Approximately 67.9 million shares have changed hands today, as compared to an average 30-day volume of 394,000 shares.

Apollo Investment Corp is US-based closed-end non-diversified management investment company. The company’s investment objective is to generate current income and capital appreciation. It mainly invests in various forms of debt investments such as secured and unsecured debt, loan investments and equity in private middle-market companies as well as public companies and in structured products. The company’s portfolio includes secured and unsecured debt of private middle-market companies and equity interests such as common stock, preferred stock, warrants or options. It generates its revenue primarily in the form of interest and dividend income from the securities and capital gains on investment securities in portfolio companies.

In the past 52 weeks, Apollo Investment Corporation share prices are bracketed by a current low of $4.95 and a high of $15.27 and is now at $13.27.

Apollo Investment Corporation (NASDAQ:AINV) is currently priced 8.0% above its average consensus analyst price target of $12.21.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

AIkido Pharma Inc. (NASDAQ:AIKI) traded at a new 52-week high today of $2.74. This new high was reached on above average trading volume as 246.1 million shares traded hands, while the average 30-day volume is approximately 1.4 million shares.

AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

AIkido Pharma Inc. share prices have moved between a 52-week high of $1.21 and the current low of $0.34 and are currently at $0.40 per share.

AIkido Pharma Inc. (NASDAQ:AIKI) has potential upside of 4.9% based on a current price of $0.40 and analysts’ consensus price target of $0.42.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Aesthetic Medical International Holdings Group Ltd. (NASDAQ:AIH) traded today at a new 52-week high of $12.39. So far today approximately 9.7 million shares have been exchanged, as compared to an average 30-day volume of 45,000 shares.

Aesthetic Medical International Holdings Group Ltd. (NASDAQ:AIH) defies analysts with a current price ($1.60) 27.4% above its average consensus price target of $1.16.

In the past 52 weeks, Aesthetic Medical International Holdings Group Ltd. share prices are bracketed by a current low of $1.17 and a high of $11.24 and is now at $1.60.

Aesthetic Medical International Holdings Group Ltd provides aesthetic medical services in China. The company generates revenue from three service offerings: non-surgical aesthetic medical services, comprising minimally invasive aesthetic treatments and energy-based treatments; surgical aesthetic medical services, and general healthcare services and other aesthetic medical services. Most of the firm’s revenue gets derived from Non-surgical aesthetic medical services. Geographically, it derives revenue from China.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

AdaptHealth Corp. (NASDAQ:AHCO) traded at a new 52-week high today of $42.64. So far today approximately 14.7 million shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.

AdaptHealth Corp is a provider of home healthcare equipment and related services. Its products portfolio includes Mobility Products, Sleep Therapy and Sleep Therapy Supplies, Respiratory Therapy, Non-invasive Ventilation, Nutrition Supplies, Bed Lifts, Seat Lift Chairs, Home Modifications, Power Mobility, and Bath Aids.

AdaptHealth Corp. share prices have moved between a 52-week high of $38.66 and the current low of $8.01 and are currently at $15.73 per share.

AdaptHealth Corp. (NASDAQ:AHCO) is currently priced 0.3% above its average consensus analyst price target of $15.68.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) traded at a new 52-week high today of $18.44. Approximately 62.5 million shares have changed hands today, as compared to an average 30-day volume of 718,000 shares.

Potential upside of 20.2% exists for Applied Genetic Technologies Corporation, based on a current level of $1.06 and analysts’ average consensus price target of $1.27.

Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.

Over the past year, Applied Genetic Technologies Corporation has traded in a range of $1.04 to $4.86 and is now at $1.06.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of AGM Group Holdings Inc. (NASDAQ:AGMH) traded at a new 52-week high today of $52.00. Approximately 7.4 million shares have changed hands today, as compared to an average 30-day volume of 382,000 shares.

AGM Group Holdings Inc through its subsidiaries is engaged in financial technology and investment business. The company offers trading platform solutions and enhancing technologies for brokerage firms and other financial institutions. The company derives revenue from the sale of the packaged software products; technical support plans and software customization services.

AGM Group Holdings Inc. (NASDAQ:AGMH) has potential upside of 371.0% based on a current price of $2.07 and analysts’ consensus price target of $9.75.

In the past 52 weeks, AGM Group Holdings Inc. share prices are bracketed by a current low of $1.38 and a high of $26.50 and is now at $2.07.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Agenus Inc. (NASDAQ:AGEN) traded today at a new 52-week high of $7.49. This new high was reached on above average trading volume as 224.7 million shares traded hands, while the average 30-day volume is approximately 4.6 million shares.

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company’s portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

Over the past year, Agenus Inc. has traded in a range of $1.55 to $6.79 and is now at $2.42.

Agenus Inc. (NASDAQ:AGEN) has potential upside of 6.5% based on a current price of $2.42 and analysts’ consensus price target of $2.58.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of AudioEye Inc. (NASDAQ:AEYE) traded at a new 52-week high today of $49.00. This new high was reached on above average trading volume as 6 million shares traded hands, while the average 30-day volume is approximately 32,000 shares.

AudioEye Inc is an industry-leading software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, AudioEye is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the FCC, ADP, SSA, Uber, and more, AudioEye helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.

In the past 52 weeks, AudioEye Inc. share prices are bracketed by a current low of $1.94 and a high of $30.40 and is now at $5.78.

AudioEye Inc. (NASDAQ:AEYE) has potential upside of 9.4% based on a current price of $5.78 and analysts’ consensus price target of $6.32.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) traded at a new 52-week high today of $74.60. This new high was reached on above average trading volume as 51.6 million shares traded hands, while the average 30-day volume is approximately 931,000 shares.

In the past 52 weeks, shares of Aerie Pharmaceuticals Inc. have traded between a low of $5.46 and a high of $74.60 and is now at $8.17, which is 50% above that low price.

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) has potential upside of 5.1% based on a current price of $8.17 and analysts’ consensus price target of $8.59.

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Adverum Biotechnologies Inc. (NASDAQ:ADVM) traded at a new 52-week high today of $26.97. This new high was reached on above average trading volume as 89.6 million shares traded hands, while the average 30-day volume is approximately 1.1 million shares.

Adverum Biotechnologies Inc. share prices have moved between a 52-week high of $10.33 and the current low of $1.21 and are currently at $1.24 per share.

There is potential upside of 7.4% for shares of Adverum Biotechnologies Inc. based on a current price of $1.24 and an average consensus analyst price target of $1.33.

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Automatic Data Processing Inc. (NASDAQ:ADP) traded at a new 52-week high today of $249.95. Approximately 133.9 million shares have changed hands today, as compared to an average 30-day volume of 2 million shares.

Over the past year, Automatic Data Processing Inc. has traded in a range of $84.38 to $248.96 and is now at $238.59.

Automatic Data Processing Inc. (NASDAQ:ADP) is currently priced 6.2% above its average consensus analyst price target of $223.74.

ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 920,000 clients primarily in the United States. ADP’s employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Archer-Daniels-Midland Company (NYSE:ADM) traded today at $96.03, eclipsing its 52-week high. This new high was reached on below average trading volume as 1.1 million shares traded hands, while the average 30-day volume is approximately 4.6 million shares.

Based on a current price of $94.48, Archer-Daniels-Midland Company is currently 1.6% above its average consensus analyst price target of $92.93.

Archer Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients.

In the past 52 weeks, Archer-Daniels-Midland Company share prices are bracketed by a low of $56.91 and a high of $96.03 and is now at $94.48, 66% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Adial Pharmaceuticals Inc (NASDAQ:ADIL) traded at a new 52-week high today of $9.43. So far today approximately 61.1 million shares have been exchanged, as compared to an average 30-day volume of 98,000 shares.

Adial Pharmaceuticals Inc has overhead space with shares priced $1.82, or 3.7% below the average consensus analyst price target of $1.89.

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Adial Pharmaceuticals Inc share prices have moved between a 52-week high of $5.08 and the current low of $1.02 and are currently at $1.82 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Advanced Emissions Solutions Inc. (NASDAQ:ADES) traded today at $15.25, eclipsing its 52-week high. So far today approximately 18.5 million shares have been exchanged, as compared to an average 30-day volume of 140,000 shares.

Over the past year, Advanced Emissions Solutions Inc. has traded in a range of $3.53 to $8.41 and is now at $6.23.

Advanced Emissions Solutions Inc is a holding company that provides emissions solutions to customers in the coal-fired power generation, industrial boiler, and cement industries. The company has two reportable segments namely Refined Coal which provides a reduction of mercury and nitrogen oxide emissions at select coal-fired power generators through the production and sale of Refined Coal; and the APT segment.

Based on a current price of $6.23, Advanced Emissions Solutions Inc. is currently 0.3% above its average consensus analyst price target of $6.21.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded at a new 52-week high today of $14.60. Approximately 89.8 million shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares.

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Adaptimmune Therapeutics plc share prices have moved between a 52-week high of $6.86 and the current low of $0.71 and are currently at $2.20 per share.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) is currently priced 2.6% above its average consensus analyst price target of $2.14.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Immunovant Inc. (NASDAQ:IMVT) traded at a new 52-week high today of $53.61. Approximately 19.8 million shares have changed hands today, as compared to an average 30-day volume of 677,000 shares.

Based on a current price of $5.05, Immunovant Inc. is currently 0.1% above its average consensus analyst price target of $5.04.

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company’s product includes IMVT-1401 targets the neonatal Fc receptor (FcRn).

Immunovant Inc. share prices have moved between a 52-week high of $16.95 and the current low of $4.98 and are currently at $5.05 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IMV Inc. (NASDAQ:IMV) traded at a new 52-week high today of $9.50. So far today approximately 43.7 million shares have been exchanged, as compared to an average 30-day volume of 99,000 shares.

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.

Potential upside of 2.9% exists for IMV Inc., based on a current level of $1.40 and analysts’ average consensus price target of $1.44.

Over the past year, IMV Inc. has traded in a range of $1.05 to $9.50 and is now at $1.40, 33% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Immersion Corporation (NASDAQ:IMMR) traded at a new 52-week high today of $18.00. This new high was reached on above average trading volume as 55.5 million shares traded hands, while the average 30-day volume is approximately 368,000 shares.

Immersion Corp is focused on the creation, design, development, and licensing of innovative haptic technologies that allow people to use its sense of touch more fully as they engage with products and experience the digital world. The company’s software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Korea.

Immersion Corporation (NASDAQ:IMMR) has potential upside of 3.5% based on a current price of $5.05 and analysts’ consensus price target of $5.23.

Over the past year, Immersion Corporation has traded in a range of $4.38 to $9.78 and is now at $5.05.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Immutep Limited (NASDAQ:IMMP) traded at a new 52-week high today of $7.95. So far today approximately 97.5 million shares have been exchanged, as compared to an average 30-day volume of 184,000 shares.

Over the past year, Immutep Limited has traded in a range of $0.53 to $5.44 and is now at $2.70.

Immutep Limited has overhead space with shares priced $2.70, or 5.3% below the average consensus analyst price target of $2.85.

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives most of the revenue from the sale of the products.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

International Media Acquisition Corp. (NASDAQ:IMAQ) traded today at a new 52-week high of $10.75. So far today approximately 1.2 million shares have been exchanged, as compared to an average 30-day volume of 56,000 shares.

International Media Acquisition Corp is a blank check company.

In the past 52 weeks, International Media Acquisition Corp. share prices are bracketed by a low of $9.61 and a high of $10.75 and is now at $9.92, 3% above that low price.

Based on a current price of $9.92, International Media Acquisition Corp. is currently 0.2% above its average consensus analyst price target of $9.90.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Inhibikase Therapeutics Inc. (NASDAQ:IKT) traded at a new 52-week high today of $11.80. This new high was reached on above average trading volume as 11.5 million shares traded hands, while the average 30-day volume is approximately 94,000 shares.

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson’s disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Inhibikase Therapeutics Inc. (NASDAQ:IKT) defies analysts with a current price ($1.40) 7.9% above its average consensus price target of $1.29.

Over the past year, Inhibikase Therapeutics Inc. has traded in a range of $0.90 to $6.41 and is now at $1.40.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Ikena Oncology Inc. (NASDAQ:IKNA) traded today at a new 52-week high of $37.61. Approximately 1.7 million shares have changed hands today, as compared to an average 30-day volume of 139,000 shares.

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

Based on a current price of $6.75, Ikena Oncology Inc. is currently 10.2% above its average consensus analyst price target of $6.06.

Over the past year, Ikena Oncology Inc. has traded in a range of $5.07 to $37.61 and is now at $6.75, 33% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of II-VI Incorporated (NASDAQ:IIVI) traded today at $100.44, eclipsing its 52-week high. So far today approximately 66.9 million shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.

There is potential upside of 9.1% for shares of II-VI Incorporated based on a current price of $67.68 and an average consensus analyst price target of $73.87.

II-VI Inc manufactures engineered materials, optoelectronic components and products used in industrial, optical communications, military, semiconductor, consumer, and life science applications. The firm operates in two segments Photonic Solutions Segment and Compound Semiconductors Segment. The Photonic Solutions Segment leverages II-VI’s compound semiconductor technology platforms to deliver components and subsystems. The Compound Semiconductors Segment is a market leader in differentiated materials and devices.

II-VI Incorporated share prices have moved between a 52-week high of $83.45 and the current low of $1.10 and are currently at $67.68 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IntriCon Corporation (NASDAQ:IIN) traded today at a new 52-week high of $76.80. Approximately 8.6 million shares have changed hands today, as compared to an average 30-day volume of 199,000 shares.

IntriCon Corp is an international company and joint development manufacturer (JDM) of micromedical components, sub-assemblies and final devices. The company serves as a JDM partner to medical device original equipment manufacturers by designing, developing, engineering, manufacturing, packaging and distributing micromedical products for high growth markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. It manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete body-worn devices for leading and emerging medical device manufacturers.

IntriCon Corporation (NASDAQ:IIN) defies analysts with a current price ($24.00) 0.0% above its average consensus price target of $23.99.

In the past 52 weeks, shares of IntriCon Corporation have traded between the current low of $4.17 and a high of $26.66 and is now at $24.00.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Information Services Group Inc. (NASDAQ:III) traded today at a new 52-week high of $9.71. This new high was reached on above average trading volume as 13.3 million shares traded hands, while the average 30-day volume is approximately 331,000 shares.

Information Services Group Inc is a US-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology strategy & operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific.

Information Services Group Inc. has overhead space with shares priced $6.77, or 0.3% below the average consensus analyst price target of $6.79.

Over the past year, Information Services Group Inc. has traded in a range of $1.61 to $9.70 and is now at $6.77.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of iHeartMedia Inc. (NASDAQ:IHRT) traded at a new 52-week high today of $28.83. Approximately 23.9 million shares have changed hands today, as compared to an average 30-day volume of 623,000 shares.

In the past 52 weeks, iHeartMedia Inc. share prices are bracketed by a current low of $4.32 and a high of $28.24 and is now at $18.62.

iHeartMedia Inc is a US-based diversified media and entertainment company. It operates through the segments of the Multiplatform Group, the Digital Audio Group and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company’s Broadcast radio, Networks and Sponsorships and Events businesses. The Digital Audio Group segment includes all of the company’s digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

There is potential upside of 1.9% for shares of iHeartMedia Inc. based on a current price of $18.62 and an average consensus analyst price target of $18.97.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded at a new 52-week high today of $185.00. So far today approximately 89.2 million shares have been exchanged, as compared to an average 30-day volume of 923,000 shares.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is currently priced 2.3% above its average consensus analyst price target of $17.61.

Intercept Pharmaceuticals Inc. share prices have moved between a 52-week high of $185.00 and a 52-week low of $11.60 and are now trading 55% above that low price at $18.03 per share.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of iCad Inc. (NASDAQ:ICAD) traded at a new 52-week high today of $24.00. Approximately 15 million shares have changed hands today, as compared to an average 30-day volume of 187,000 shares.

There is potential upside of 3.0% for shares of iCad Inc. based on a current price of $3.89 and an average consensus analyst price target of $4.00.

iCad Inc. share prices have moved between a 52-week high of $21.24 and the current low of $2.50 and are currently at $3.89 per share.

icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed a technology namely Xoft Axxent electronic brachytherapy system used in the treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of ImmunityBio Inc. (NASDAQ:IBRX) traded today at $40.56, eclipsing its 52-week high. This new high was reached on above average trading volume as 26.9 million shares traded hands, while the average 30-day volume is approximately 1.3 million shares.

ImmunityBio Inc. has overhead space with shares priced $5.35, or 7.5% below the average consensus analyst price target of $5.79.

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

In the past 52 weeks, ImmunityBio Inc. share prices are bracketed by a current low of $4.81 and a high of $21.50 and is now at $5.35.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) traded today at a new 52-week high of $121.50. Approximately 249 million shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares.

Over the past year, Horizon Therapeutics Public Limited Company has traded in a range of $9.45 to $120.53 and is now at $109.66.

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is currently priced 2.0% above its average consensus analyst price target of $107.49.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Huazhu Group Limited (NASDAQ:HTHT) traded at a new 52-week high today of $177.20. Approximately 62 million shares have changed hands today, as compared to an average 30-day volume of 2.7 million shares.

There is potential upside of 7.0% for shares of Huazhu Group Limited based on a current price of $32.59 and an average consensus analyst price target of $34.87.

Huazhu Group Ltd is a China-based hotel group. It operates in the leased, manachised and franchised models. The lease model involves operating hotels located on leased properties. The manachised model involves management of hotels through on-site hotel managers appointed by the group and fees are collected from franchisees. The franchise model includes providing training and reservation and support services to the franchised hotels but on-site hotel managers are not appointed. Brands under which it operates hotels are Joya Hotel, Manxin Hotels and Resorts, JI Hotel, Starway Hotel, Elan Hotel, HanTing Hotel, and Hi Inn. Revenues are derived from operating leased hotels and franchise and service fees from their manachised and franchised hotels.

In the past 52 weeks, Huazhu Group Limited share prices are bracketed by a current low of $21.80 and a high of $61.51 and is now at $32.59.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of The Hershey Company (NYSE:HSY) traded today at $223.45, eclipsing its 52-week high. So far today approximately 202,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares.

Based on a current price of $221.70, The Hershey Company is currently 1.5% above its average consensus analyst price target of $218.28.

Hershey is a leading confectionery manufacturer in the U.S. (nearly a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm’s mix has expanded over the last 85 years and now consists of 100 brands, including Reese’s, Kit Kat, Kisses, and Ice Breakers. Hershey’s products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate’s Booty, Smart Puffs, and Original Tings brands) over the past few years.

Over the past year, The Hershey Company has traded in a range of $156.87 to $223.45 and is now at $221.70, 41% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Histogen Inc. (NASDAQ:HSTO) traded today at $5.09, eclipsing its 52-week high. Approximately 54.4 million shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares.

Histogen Inc. has overhead space with shares priced $0.23, or 40.6% below the average consensus analyst price target of $0.39.

Over the past year, Histogen Inc. has traded in a range of $0.19 to $1.26 and is now at $0.23.

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Heron Therapeutics Inc. (NASDAQ:HRTX) traded today at a new 52-week high of $42.80. Approximately 85.4 million shares have changed hands today, as compared to an average 30-day volume of 2.8 million shares.

Based on a current price of $6.09, Heron Therapeutics Inc. is currently 0.7% above its average consensus analyst price target of $6.05.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company’s product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

In the past 52 weeks, shares of Heron Therapeutics Inc. have traded between a low of $4.58 and a high of $42.80 and is now at $6.09, which is 33% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of HealthEquity Inc. (NASDAQ:HQY) traded at a new 52-week high today of $101.32. So far today approximately 42.6 million shares have been exchanged, as compared to an average 30-day volume of 723,000 shares.

Over the past year, HealthEquity Inc. has traded in a range of $22.45 to $84.78 and is now at $67.76.

HealthEquity Inc. (NASDAQ:HQY) defies analysts with a current price ($67.76) 0.8% above its average consensus price target of $67.20.

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. Its technology allows customers to see their tax-advantaged healthcare savings, compare treatment options and pricing, pay healthcare bills, receive benefit information, and earn wellness incentives. The firm primarily partners with health plans and employers and serves as the custodian of its customers’ health savings accounts (HSAs). HealthEquity also engages in reimbursement arrangements and offers healthcare incentives to its members. In addition, the company provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

HP Inc. (NYSE:HPQ) traded at a new 52-week high today of $41.41. Approximately 51 million shares have changed hands today, as compared to an average 30-day volume of 18.6 million shares.

HP Inc. is a leading provider of computers, printers, and printer supplies. The company’s three operating business segments are its personal systems, containing notebooks, desktops, and workstations; and its printing segment which contains supplies, consumer hardware, and commercial hardware; and corporate investments. In 2015, Hewlett-Packard was separated into HP Inc. and Hewlett Packard Enterprise and the Palo Alto, California-based company sells on a global scale.

Based on a current price of $41.12, HP Inc. is currently 14.5% above its average consensus analyst price target of $35.18.

In the past 52 weeks, HP Inc. share prices are bracketed by a low of $26.11 and a high of $41.41 and is now at $41.12, 57% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Helmerich & Payne Inc. (NYSE:HP) traded at a new 52-week high today of $45.80. So far today approximately 291,000 shares have been exchanged, as compared to an average 30-day volume of 1.8 million shares.

Over the past year, Helmerich & Payne Inc. has traded in a range of $20.93 to $45.80 and is now at $44.78, 114% above that low.

Helmerich & Payne has the largest fleet of U.S. land drilling rigs. The company’s FlexRig line is the leading choice to drill horizontal wells for production of U.S. tight oil and gas. H&P is present in nearly every major U.S. shale play and also has a small presence internationally.

There is potential upside of 4.2% for shares of Helmerich & Payne Inc. based on a current price of $44.78 and an average consensus analyst price target of $46.66.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Hollysys Automation Technologies Ltd. (NASDAQ:HOLI) traded today at a new 52-week high of $28.09. This new high was reached on above average trading volume as 25 million shares traded hands, while the average 30-day volume is approximately 596,000 shares.

Hollysys Automation Technologies Ltd is a China-based company that provides automation and control technologies and products. The company operates through three segments. Its IA segment supplies solutions including third-party hardware-centric products, proprietary software products, and others. The Rail segment supplies train control center and automation train protection to the rail and subway industries. The M&E segment consists of its two Southeast Asia-based subsidiaries that provide mechanical and electrical solutions. Hollysys Automation Technologies generates most of its sales from the Chinese domestic market.

Hollysys Automation Technologies Ltd. has overhead space with shares priced $16.13, or 10.3% below the average consensus analyst price target of $17.98.

In the past 52 weeks, Hollysys Automation Technologies Ltd. share prices are bracketed by a current low of $9.64 and a high of $21.24 and is now at $16.13.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Hemisphere Media Group Inc. (NASDAQ:HMTV) traded at a new 52-week high today of $15.28. So far today approximately 2.7 million shares have been exchanged, as compared to an average 30-day volume of 104,000 shares.

Hemisphere Media Group Inc is a Spanish-language media company. It owns and operates several Spanish-language networks and content production platform, including movie and telenovela channels, Hispanic entertainment genres, and the cable television networks. The several Spanish Spanish-language networks and content production platform owned by the company includes Cinelatino, WAPA, WAPA America, Pasiones, Centroamerica TV and Television Dominicana. The company operates through a single segment being the operation of Spanish-language Networks and content platforms. Hemisphere generates revenue from the sale of advertising and broadcasting.

In the past 52 weeks, shares of Hemisphere Media Group Inc. have traded between a low of $4.31 and a high of $15.28 and is now at $4.39, which is 2% above that low price.

There is potential upside of 4.0% for shares of Hemisphere Media Group Inc. based on a current price of $4.39 and an average consensus analyst price target of $4.56.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Hillman Solutions Corp. (NASDAQ:HLMN) traded at a new 52-week high today of $13.50. So far today approximately 7.9 million shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares.

There is potential upside of 5.9% for shares of Hillman Solutions Corp. based on a current price of $11.32 and an average consensus analyst price target of $11.98.

Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder’s hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the group are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the US, Canada and Mexico.

In the past 52 weeks, shares of Hillman Solutions Corp. have traded between the current low of $8.12 and a high of $13.46 and is now at $11.32.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Shares of Harmonic Inc. (NASDAQ:HLIT) traded today at $12.37, eclipsing its 52-week high. This new high was reached on above average trading volume as 42.4 million shares traded hands, while the average 30-day volume is approximately 589,000 shares.

Over the past year, Harmonic Inc. has traded in a range of $2.52 to $12.22 and is now at $8.70.

Harmonic Inc designs and manufactures video infrastructure products and system solutions to deliver video and broadband services to consumer devices. The firm operates in two segments: Video, which sells video processing, production, and playout solutions to cable operators and satellite and telecommunications providers; and Cable Access, which sells cable edge solutions to cable operators. Roughly half of the firm’s revenue is generated in the Americas, with the rest coming from Europe, the Middle East, and Africa, as well as the Asia Pacific region.

Harmonic Inc. (NASDAQ:HLIT) has potential upside of 3.4% based on a current price of $8.70 and analysts’ consensus price target of $9.00.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Hibbett Inc. (NASDAQ:HIBB) traded today at a new 52-week high of $106.00. This new high was reached on above average trading volume as 46.1 million shares traded hands, while the average 30-day volume is approximately 592,000 shares.

Over the past year, Hibbett Inc. has traded in a range of $1.10 to $101.65 and is now at $41.66.

Hibbett Inc is engaged in the retail of sports goods. The company operates small to midsize stores and focuses its business on the South, Southwest, mid-Atlantic, and Midwest areas of the country. It offers a broad range of sporting goods, including apparel, footwear, accessories, and equipment needed for team sports, with brands such as Nike, Under Armour, Adidas, The North Face, Jordan, Costa, and others. The company consists of three kinds of stores: Hibbett Sports, the company’s primary retail format stores, accounting for most of the company’s total stores, City Gear, and Sports Additions, smaller-format stores primarily offering athletic footwear with a fashion-based style.

Hibbett Inc. (NASDAQ:HIBB) has potential upside of 5.5% based on a current price of $41.66 and analysts’ consensus price target of $43.96.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Turtle Beach Corporation (NASDAQ:HEAR) traded today at a new 52-week high of $38.81. This new high was reached on above average trading volume as 105.4 million shares traded hands, while the average 30-day volume is approximately 612,000 shares.

Turtle Beach Corp is gaming audio and accessory brand offering a broad selection of gaming headsets for Xbox, PlayStation, and Nintendo consoles, as well as for PC, Mac, and mobile/tablet devices. The company’s portfolio includes gaming headsets, PC gaming headsets, PC gaming keyboards, PC gaming mice and other accessories which are distributed internationally in North America, South America, Europe, the Middle East, Africa, Australia, and Asia sold at thousands of storefronts, including retailers such as Amazon, Argos, Best Buy, GAME, GameStop, EB Games, Media Markt, Saturn, Target and Walmart.

Potential upside of 1.5% exists for Turtle Beach Corporation, based on a current level of $20.54 and analysts’ average consensus price target of $20.86.

In the past 52 weeks, shares of Turtle Beach Corporation have traded between the current low of $0.41 and a high of $38.70 and is now at $20.54.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer